Evidence map›Paper›PMID 40174880›Full record

ArticleApplied clinical informatics2025

Facilitators and Barriers to Uptake of Drug-Drug Interaction Alerts: Perspectives of Australian End Users and Managers.

Kristian Stanceski, Bethany A Van Dort, Teresa Lee, Andrew J McLachlan, Richard O Day, Sarah N Hilmer, Ling Li, Johanna Westbrook, Wu Yi Zheng, Michael Barras and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied clinical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kristian StanceskiFaculty of Medicine and Health, Biomedical Informatics and Digital Health, School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
Bethany A Van DortFaculty of Medicine and Health, Biomedical Informatics and Digital Health, School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
Teresa LeeSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
Andrew J McLachlanSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.
Richard O DayDepartment of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.
Sarah N HilmerDepartments of Clinical Pharmacology and Aged Care, Kolling Institute of Medical Research, Faculty of Medicine and Health, The University of Sydney and Northern Sydney Local Health District, St Leonards, New South Wales, Australia.
Ling LiAustralian Institute of Health Innovation, Centre for Health Systems and Safety Research, Macquarie University, North Ryde, New South Wales, Australia.
Johanna WestbrookAustralian Institute of Health Innovation, Centre for Health Systems and Safety Research, Macquarie University, North Ryde, New South Wales, Australia.
Wu Yi ZhengFaculty of Medicine and Health, Biomedical Informatics and Digital Health, School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
Michael BarrasPharmacy Department, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Karma Z S MekhailPharmacy Department, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia.
Melissa T BaysariFaculty of Medicine and Health, Biomedical Informatics and Digital Health, School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-drug interaction (DDI) alerts in electronic systems are frequently implemented to minimize the occurrence of preventable DDIs. While prescribers recognize the potential benefits of DDI alerts, a large proportion are overridden by users.

objectivesThis study aimed to explore and compare prescribers' and managers' perspectives of DDI alerts.

methodsA qualitative descriptive study was conducted across six hospitals in Australia with end users (prescribers who receive alerts) [

resultsEnd users predominantly reflected on the utility of the DDI alert system (i.e. how useful it was to their role), less on how easy the system was to use, and mainly focused on the negative consequences of alerts. Managers believed the benefits of DDI alerts are primarily experienced by junior doctors. While end users suggested that alerts should be tailored to the patient's clinical scenario, managers called for DDI alerts to be tailored to the prescriber (seniority and specialty).

conclusionInterviews with end users and managers uncovered a number of perceived benefits and limitations of DDI alerts, primarily related to the system's usefulness. While largely consistent, some perceptions were different between end users and managers, particularly in the types of benefits, and how they conceptualized potential tailoring to improve DDI alerts. Our findings point to a need for user participation in the development, deployment, and improvement of alerts to promote consideration and effectiveness of DDI alerts.

Indexed as

Attitude of Health PersonnelMedical Order Entry SystemsAustraliaDrug InteractionsHumans

Identifiers

PMID40174880
PMCPMC11964717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.